Hiromichi Ebi

Hiromichi Ebi

UNVERIFIED PROFILE

Are you Hiromichi Ebi?   Register this Author

Register author
Hiromichi Ebi

Hiromichi Ebi

Publications by authors named "Hiromichi Ebi"

Are you Hiromichi Ebi?   Register this Author

49Publications

1476Reads

16Profile Views

Respecting your elders: osimertinib demonstrates preferential activity in elderly patients with T790M positive non-small cell lung cancers.

J Thorac Dis 2019 Sep;11(Suppl 15):S1844-S1846

Philips Institute for Oral Health Research, VCU School of Dentistry and Massey Cancer Center, Richmond, VA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd.2019.08.122DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6783766PMC
September 2019

Anaplastic lymphoma kinase expression in small-cell lung cancer.

Histopathology 2019 Jul 23;75(1):20-28. Epub 2019 May 23.

Department of Pathology and Molecular Diagnostics, Aichi Cancer Centre, Nagoya, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/his.13842DOI Listing
July 2019

The ADAM17 Protease Promotes Tobacco Smoke Carcinogen-induced Lung Tumourigenesis.

Carcinogenesis 2019 Jun 27. Epub 2019 Jun 27.

Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/carcin/bgz123DOI Listing
June 2019

Pulmonary carcinosarcoma showing an obvious response to pazopanib: a case report.

BMC Pulm Med 2018 Dec 12;18(1):193. Epub 2018 Dec 12.

Division of Medical Oncology, Cancer Research Institute, Kanazawa University, 13-1, Takara-machi, Kanazawa, Ishikawa, 920-0934, Japan.

View Article

Download full-text PDF

Source
https://bmcpulmmed.biomedcentral.com/articles/10.1186/s12890
Publisher Site
http://dx.doi.org/10.1186/s12890-018-0757-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291996PMC
December 2018

Distinct dependencies on receptor tyrosine kinases in the regulation of MAPK signaling between BRAF V600E and non-V600E mutant lung cancers.

Oncogene 2018 03 19;37(13):1775-1787. Epub 2018 Jan 19.

Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Ishikawa, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41388-017-0035-9DOI Listing
March 2018

Resistance mediated by alternative receptor tyrosine kinases in FGFR1-amplified lung cancer.

Carcinogenesis 2017 10;38(11):1063-1072

Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Ishikawa 920-0934, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/carcin/bgx091DOI Listing
October 2017

Key roles of EMT for adaptive resistance to MEK inhibitor in KRAS mutant lung cancer.

Small GTPases 2017 07 8;8(3):172-176. Epub 2016 Jul 8.

a Division of Medical Oncology , Cancer Research Institute, Kanazawa University , Ishikawa , Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/21541248.2016.1210369DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5584737PMC
July 2017

Lack of association between the BIM deletion polymorphism and the risk of lung cancer with and without EGFR mutations.

J Thorac Oncol 2015 Jan;10(1):59-66

*Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan; †Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Aichi, Japan; ‡Center for Genomic Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan; §Thoracic Surgery, Aichi Cancer Center Hospital, Aichi, Japan; ‖Department of Thoracic Oncology, Aichi Cancer Center Hospital, Aichi, Japan; ¶VCU Philips Institute for Oral Health Research, School of Dentistry and Massey Cancer Center, Virginia Commonwealth University, Richmond, VA; #Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Aichi, Japan; **Department of Surgery, Division of Thoracic Surgery, Kinki University Faculty of Medicine, Osaka-Sayama, Japan; and ††Department of Preventive Medicine, Kyushu University Faculty of Medical Sciences, Fukuoka, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000371DOI Listing
January 2015

Triple inhibition of EGFR, Met, and VEGF suppresses regrowth of HGF-triggered, erlotinib-resistant lung cancer harboring an EGFR mutation.

J Thorac Oncol 2014 Jun;9(6):775-83

Divisions of *Medical Oncology and †Tumor Dynamics and Regulation, Cancer Research Institute, Kanazawa University, Kanazawa, Japan; and ‡Tsukuba Research Center, Taiho Pharmaceutical Co., Ltd., Tsukuba, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000170DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4132034PMC
June 2014

Not just gRASping at flaws: finding vulnerabilities to develop novel therapies for treating KRAS mutant cancers.

Cancer Sci 2014 May 26;105(5):499-505. Epub 2014 Mar 26.

Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Ishikawa, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cas.12383DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4317830PMC
May 2014

mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1.

Cancer Discov 2014 Jan 25;4(1):42-52. Epub 2013 Oct 25.

1Massachusetts General Hospital Cancer Center; 2Department of Medicine, Harvard Medical School; 3Division of Gastroenterology, Department of Medicine, Tufts Medical Center; 4Department of Pathology, Massachusetts General Hospital, Boston; and 5Radiation Oncology, Steele Lab for Tumor Biology, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-13-0315DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3973435PMC
January 2014

EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition.

Cancer Res 2013 Apr 4;73(8):2428-34. Epub 2013 Feb 4.

Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Ishikawa, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-12-3479DOI Listing
April 2013

Apoptosis in targeted therapy responses: the role of BIM.

Adv Pharmacol 2012 ;65:519-42

Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02129, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/B978-0-12-397927-8.00016-6DOI Listing
February 2013

Relationship of deregulated signaling converging onto mTOR with prognosis and classification of lung adenocarcinoma shown by two independent in silico analyses.

Cancer Res 2009 May 21;69(9):4027-35. Epub 2009 Apr 21.

Division of Molecular Carcinogenesis, Center for Neurological Diseases and Cancer, Nagoya University Graduate School of Medicine, Nagoya, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-08-3403DOI Listing
May 2009

Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors.

Cancer Sci 2008 Jul 12;99(7):1492-8. Epub 2008 May 12.

Oncology/Hematology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1349-7006.2008.00837.xDOI Listing
July 2008

Novel NBS1 heterozygous germ line mutation causing MRE11-binding domain loss predisposes to common types of cancer.

Cancer Res 2007 Dec;67(23):11158-65

Division of Molecular Carcinogenesis, Center for Neurological Diseases and Cancer, Nagoya University Graduate School of Medicine, Showa-ku, Nagoya 466-8550, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-07-1749DOI Listing
December 2007

Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients.

Pharmacogenet Genomics 2007 Jun;17(6):431-45

Drug Metabolism and Toxicology, Division of Pharmaceutical Sciences, Graduate School of Medical Science, Kanazawa University, Kakuma-machi, Kanazawa 920-1192, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FPC.0b013e328045c4fbDOI Listing
June 2007

[Pharmacokinetic comparison of capecitabine and 5'-deoxy-5-fluorouridine (doxifluridine; 5'-DFUR)].

Gan To Kagaku Ryoho 2005 Dec;32(13):2053-7

Division of Oncology & Hematology, Dept. of Medicine, National Cancer Center Hospital East.

View Article

Download full-text PDF

Source
December 2005

Pharmacokinetic and pharmacodynamic comparison of fluoropyrimidine derivatives, capecitabine and 5'-deoxy-5-fluorouridine (5'-DFUR).

Cancer Chemother Pharmacol 2005 Aug 21;56(2):205-11. Epub 2005 Apr 21.

Division of Oncology/Hematology, Department of Medicine, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-004-0934-7DOI Listing
August 2005

Identification of decatenation G2 checkpoint impairment independently of DNA damage G2 checkpoint in human lung cancer cell lines.

Cancer Res 2004 Jul;64(14):4826-32

Division of Molecular Oncology, Aichi Cancer Center Research Institute, 1-1 Kanokoden, Chukusa-ku, Nagoya 464-8681, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-04-0871DOI Listing
July 2004

Extragonadal germ cell tumors in Japan.

Cancer Sci 2003 Dec;94(12):1107-11

Division of Oncology/Hematology, Department of Medicine, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1349-7006.2003.tb01408.xDOI Listing
December 2003

[Rationale for Herceptin in the clinical use].

Nihon Rinsho 2002 Mar;60(3):463-7

Division of Hematology/Oncology, National Cancer Center Hospital East.

View Article

Download full-text PDF

Source
March 2002